Time value
Future benefits and costs are discounted so alternatives with different launch dates can be compared on a present-value basis.
Compare baseline and consulting-supported commercialization using patent life, launch timing, risk-adjusted direct and royalty benefits, complete costs, NPV, and contract thresholds.
Sample values are not market standards or official valuations. Replace them with verified quotes, contracts, patent-register data, and business-plan assumptions.
The model uses the shorter of the analysis horizon and the verified remaining protection period.
Group related national rights into patent families.
Internal decision horizon, capped at 20 years.
Enter the register-verified period after expiry and extensions.
An internal assumption reflecting funding, business, and technology risk.
Direct business and licensing portions are separated, then risk-adjusted for success and launch delay.
Total relevant revenue for the first 12 months after launch.
Compounded at each commercialization-year boundary.
Share of revenue monetized through licensing.
Contribution margin after variable costs on direct revenue.
Internal estimate of patent contribution to direct margin.
An input to validate against agreements and comparables.
Internal probability of commercialization without consulting.
Consulting-case probability under the same success definition.
Expected revenue change from portfolio and deal improvements.
Months from analysis start to first commercial cash inflow.
First cash-inflow timing including the consulting process.
Exclude sunk costs and enter only future costs that arise under both alternatives.
Current-time total for remaining R&D, validation, and prototypes.
Initial certification, marketing, and channel costs.
Annuities and other portfolio-maintenance costs.
Annual monitoring, contract, and dispute-prevention costs.
Incremental operating cost after commercialization begins.
Separate consulting-only costs from recurring portfolio savings.
Current-time fixed fee for diagnosis, strategy, and execution planning.
Separate prior-art, market, and claim-scope review cost.
Probability-weighted and recognized in the first commercial month.
Recurring fee for rights, contracts, and partner management.
Maintenance and legal savings from portfolio rationalization.
Higher-value alternative
Consulting leads
Reflects both the NPV difference and the near-tie threshold.
Incremental consulting NPV
$147,697.00
Consulting NPV minus baseline NPV.
Baseline NPV
$36,436.00
Risk-adjusted present value without consulting.
Consulting-case NPV
$184,132.00
Includes consulting costs, savings, and improvement assumptions.
| Metric | Baseline | Consulting |
|---|---|---|
| Commercial cash-flow months | 102 | 108 |
| Direct-business benefit PV | $372,705.00 | $518,302.00 |
| Royalty benefit PV | $101,416.00 | $141,035.00 |
| Total benefit PV | $474,121.00 | $659,337.00 |
| Rights and legal cost PV | $133,979.00 | $133,979.00 |
| Commercial operating cost PV | $123,706.00 | $135,369.00 |
| Consulting cost PV | $0.00 | $57,118.00 |
| Total cost PV | $437,685.00 | $475,204.00 |
| NPV | $36,436.00 | $184,132.00 |
| Benefit-cost ratio | 1.08× | 1.39× |
| ROI | 8.32% | 38.75% |
| Sustained payback month | 103.6 months | 67.5 months |
Each value changes one variable while holding the others fixed. A negative required uplift means the current probability and cost assumptions already clear baseline NPV.
Year-one cost includes time-zero remaining development, market-entry, and initial consulting costs.
| Year | Baseline Benefit | Baseline Cost | Baseline Net cash flow | Baseline Cumulative PV | Consulting Benefit | Consulting Cost | Consulting Net cash flow | Consulting Cumulative PV |
|---|---|---|---|---|---|---|---|---|
| 1 | $0.00 | $202,500.00 | -$202,500.00 | -$201,172.00 | $0.00 | $226,500.00 | -$226,500.00 | -$225,216.00 |
| 2 | $44,179.00 | $36,000.00 | $8,179.00 | -$195,030.00 | $111,330.00 | $55,050.00 | $56,280.00 | -$178,212.00 |
| 3 | $90,566.00 | $49,500.00 | $41,066.00 | -$164,272.00 | $116,897.00 | $48,750.00 | $68,147.00 | -$127,093.00 |
| 4 | $95,095.00 | $49,500.00 | $45,595.00 | -$133,779.00 | $122,742.00 | $48,750.00 | $73,992.00 | -$77,536.00 |
| 5 | $99,849.00 | $49,500.00 | $50,349.00 | -$103,711.00 | $128,879.00 | $48,750.00 | $80,129.00 | -$29,619.00 |
| 6 | $104,842.00 | $49,500.00 | $55,342.00 | -$74,201.00 | $135,323.00 | $48,750.00 | $86,573.00 | $16,604.00 |
| 7 | $110,084.00 | $49,500.00 | $60,584.00 | -$45,356.00 | $142,089.00 | $48,750.00 | $93,339.00 | $61,101.00 |
| 8 | $115,588.00 | $49,500.00 | $66,088.00 | -$17,260.00 | $149,193.00 | $48,750.00 | $100,443.00 | $103,854.00 |
| 9 | $121,368.00 | $49,500.00 | $71,868.00 | $10,021.00 | $156,653.00 | $48,750.00 | $107,903.00 | $144,861.00 |
| 10 | $127,436.00 | $49,500.00 | $77,936.00 | $36,436.00 | $164,486.00 | $48,750.00 | $115,736.00 | $184,132.00 |
Change one assumption at a time, plus the stated combined downside, to test whether the decision reverses.
| Scenario | Consulting probability | Launch delay | Fixed fee | Year-one revenue | Discount rate | Baseline NPV | Consulting-case NPV | Incremental consulting NPV | Higher-value alternative |
|---|---|---|---|---|---|---|---|---|---|
| Base | 42% | 12 | $18,750.00 | $3,375,000.00 | 12% | $36,436.00 | $184,132.00 | $147,697.00 | Consulting leads |
| Consulting probability -10pp | 32% | 12 | $18,750.00 | $3,375,000.00 | 12% | $36,436.00 | $28,474.00 | -$7,962.00 | Near tie; validate |
| Commercial revenue -20% | 42% | 12 | $18,750.00 | $2,700,000.00 | 12% | -$58,388.00 | $52,265.00 | $110,653.00 | Consulting leads |
| Consulting delay +12 months | 42% | 24 | $18,750.00 | $3,375,000.00 | 12% | $36,436.00 | $86,937.00 | $50,501.00 | Consulting leads |
| Consulting fixed fee +20% | 42% | 12 | $22,500.00 | $3,375,000.00 | 12% | $36,436.00 | $180,382.00 | $143,947.00 | Consulting leads |
| Discount rate +3pp | 42% | 12 | $18,750.00 | $3,375,000.00 | 15% | $3,111.00 | $131,271.00 | $128,160.00 | Consulting leads |
| Combined downside | 32% | 24 | $18,750.00 | $2,700,000.00 | 12% | -$58,388.00 | -$122,291.00 | -$63,902.00 | Baseline leads |
| Commercial revenue +20% | 42% | 12 | $18,750.00 | $4,050,000.00 | 12% | $131,260.00 | $316,000.00 | $184,740.00 | Consulting leads |
Official statutes, valuation standards, and the WIPO income approach were checked on 2026-08-06. This result is an internal risk-adjusted DCF comparison, not an official technology valuation, accounting or tax value, collateral or transaction price, damages estimate, freedom-to-operate analysis, or legal opinion. No official source guarantees the success probability, attribution, royalty, discount rate, or consulting performance entered here.
A portfolio creates economic value only when protected technology produces cash flow before the relevant rights and economic advantages expire.
This calculator compares a baseline commercialization plan with a consulting-supported plan using monthly, risk-adjusted discounted cash flow.
It connects portfolio rationalization, launch timing, direct-business contribution, licensing income, recurring rights costs, and consulting fees in one decision model.
Future benefits and costs are discounted so alternatives with different launch dates can be compared on a present-value basis.
Direct and royalty benefits are weighted by the entered probability of commercialization success instead of being treated as guaranteed revenue.
Cash flow ends at the shorter of the analysis horizon and the register-verified remaining protection period.
The output is an internal scenario model for budgeting, investment review, and contract negotiation.
It does not replace an accredited technology valuation, accounting or tax value, collateral or transaction price, damages analysis, freedom-to-operate review, patent-validity analysis, or legal opinion.
Revenue after launch is divided between direct commercialization and licensing.
Direct benefit uses contribution margin and patent attribution, while licensing benefit uses the entered royalty rate.
Both streams are multiplied by the success probability for the relevant alternative, and no commercial inflow is recognized before launch.
Direct benefit = revenue × direct share × contribution margin × patent attribution × success probability
Royalty benefit = revenue × licensed share × royalty rate × success probability
NPV = time-zero cost + Σ monthly net cash flow ÷ (1 + annual discount rate)month ÷ 12
The consulting case can change success probability, launch delay, and revenue while adding fixed, due-diligence, success, and recurring management fees.
Portfolio savings reduce maintenance and legal-monitoring costs but cannot exceed those entered costs.
The success fee is probability-weighted and placed in the first commercial month, while sunk costs already incurred should be excluded.
| Input area | Useful evidence | Common error |
|---|---|---|
| Rights and term | Patent registers, family map, annuity ledger | Using a nominal statutory maximum as every right’s actual remaining life |
| Revenue and growth | Product plan, customer pipeline, license term sheet | Entering total company revenue as patent-related revenue |
| Margin and attribution | Cost model, substitute analysis, value-chain review | Confusing operating margin with contribution margin or double counting attribution |
| Probability and delay | Stage-gate records, comparable projects, regulatory plan | Increasing consulting success without evidence while assuming no consulting lead time |
| Royalty rate | Draft agreement, comparable licenses, technology-specific benchmarks | Treating one industry average as a guaranteed contract rate |
| Costs and savings | Proposals, fee schedules, rights-management ledger | Including sunk cost or entering savings greater than avoidable cost |
Incremental NPV is consulting NPV minus baseline NPV. A positive result favors consulting under the entered assumptions, but its reliability depends on whether it remains positive in downside cases. Incremental ROI divides that value difference by incremental cost present value.
This is the consulting success probability that makes consulting NPV equal baseline NPV while other inputs stay fixed. Compare the threshold with a defensible probability range, not a consultant’s unsupported point estimate.
This reverse-solved fee preserves parity with baseline NPV under the other consulting assumptions. Use it as one contract-negotiation boundary, not as a market-price appraisal.
This is the first discounted cumulative break-even point after which cumulative value never turns negative again. It avoids calling a temporary recovery the final payback point.
The calculator flags a near tie when the present-value difference is within 5% of average cost present value.
In that range, investigate claim strength, market demand, comparable deals, consultant track record, and probability evidence before relying on a decimal ranking.
Compare a technology-marketing or licensing-consulting budget with expected royalty income and the savings from abandoning non-core families.
Test whether IP strategy support can accelerate launch or improve partner and investor outcomes enough to cover remaining development, certification, and advisory cost.
Evaluate recurring annuity and monitoring savings alongside the commercial benefit of concentrating resources on core patent families.
Separate fixed, success, and recurring fees, then use parity probability and maximum fixed fee to structure milestones and payment conditions.
The following primary sources were checked on 2026-08-06.
They establish legal and valuation-method boundaries; they do not prescribe the sample probabilities, royalty rate, attribution, consulting performance, or discount rate used by this calculator.
No. Enter the remaining protected period supported by current registers after considering grant status, registered adjustments or extensions, annuity status, surrender, and lapse.
No. Attribution applies to direct-business contribution margin. Royalty rate applies to the licensed revenue portion. They represent different monetization routes and should not be double counted.
Use a consistent success definition, stage-gate history, comparable projects, customer validation, regulatory and development risk, and verifiable consultant evidence. The sample value is not evidence.
Yes. Enter the longer consulting delay. The model postpones cash inflow and reduces the number of commercial months available before the horizon ends.
No. Review incremental NPV, combined downside, deliverables, liability, termination rights, patent validity, market demand, funding constraints, and independent professional advice.
Not directly. Keep one currency throughout and enter separately adjusted cash flow if your decision requires tax, inflation, or exchange-rate treatment.
A documented range that survives downside testing is more useful than one optimistic point estimate.
Save each input source and review date, then use the output as a transparent starting point for investment review and contract negotiation.